Francisco Partners has agreed to sell Aesynt to Omnicell (NASDAQ: OMCL) for a total cash consideration of $275 million. The transaction is expected to close in 2016. Aesynt provides pharmacy automation and information management tools to healthcare organizations. The combined company of Aesynt and Omnicell would have about 4,000 acute care facilities; annual revenues of more than $650 million; and roughly 2,200 employees. Aesynt reported approximately $182 million in revenue and about $20 million in adjusted EBITDA (unaudited) in the 12 months ended June 30. Francisco Partners acquired the company in 2013.